A major shift is occurring in the US life sciences landscape as researchers move away from traditional 2D cell monolayers toward more physiologically relevant 3D cell cultures, such as spheroids and organoids. These models better mimic the complex architecture and microenvironment of human tissues, providing more predictive data for clinical success. However, 3D models present unique challenges for viability testing, as reagents must penetrate deep into the cellular structure to provide an accurate count of living versus dead cells. Consequently, the US market is seeing a surge in specialized "3D-validated" assays that utilize advanced chemistry to ensure complete cell lysis or deep-tissue dye penetration.

According to data from the US Cell Viability Assays Market, the "Consumables" segment—comprising specialized plates, reagents, and dyes—remains the largest revenue contributor. US-based academic and private research institutions are increasingly adopting "Multiplexing" techniques, which allow for the simultaneous measurement of cell viability, apoptosis, and oxidative stress within a single well. This "multi-parameter" approach provides a holistic view of cellular health and is becoming a standard protocol in American toxicology labs. As the FDA continues to encourage the use of alternative methods to animal testing, the role of advanced 3D cell viability assays as a bridge to clinical trials is becoming indispensable.